Trial · NCT04569032
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment | CD30 <1% [Central Laboratory Assessment] | 61 | 95% Confidence Interval 38.5 to 80.3 | Percentage of participants | |
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment | CD30 1% to <10% [Central Laboratory Assessment] | 81 | 95% Confidence Interval 62.5 to 92.5 | Percentage of participants | |
| Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment | CD30 <1% [Central Laboratory Assessment] | 52 | 95% Confidence Interval 30.6 to 73.2 | Percentage of participants | |
| Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment | CD30 1% to <10% [Central Laboratory Assessment] | 71 | 95% Confidence Interval 52.0 to 85.8 | Percentage of participants | |
| ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment | CD30 <1% [Central Laboratory Assessment] | 57 | 95% Confidence Interval 34.5 to 76.8 | Percentage of participants | |
| ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment | CD30 1% to <10% [Central Laboratory Assessment] | 77 | 95% Confidence Interval 58.9 to 90.4 | Percentage of participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | TEAEs | 32 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | TEAEs | 46 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | TESAEs | 15 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | TESAEs | 16 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | Treatment related TEAEs | 25 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | Treatment related TEAEs | 40 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | Hemoglobin decreased: Grade 1+2 | 19 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | Hemoglobin decreased: Grade 1+2 | 34 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | Hemoglobin decreased: Grade 3 | 3 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | Hemoglobin decreased: Grade 3 | 1 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | Leukocytes decreased: Grade 1+2 | 13 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | Leukocytes decreased: Grade 1+2 | 23 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 <1% [Local Laboratory Assessment] | Leukocytes decreased: Grade 3 | 4 | Participants | |
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment | CD30 1% to <10% [Local Laboratory Assessment] | Leukocytes decreased: Grade 3 | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04569032/results